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Abstract
The tumor stroma ratio (TSR) is a promising prognostic biomarker in colon cancer, which could provide additional risk
stratification for therapy adaption. The objective of our study was the investigation of the prognostic significance of TSR at
different tumor sites in a simple semiautomatic approach with the open-source program ImageJ. We investigated 206 pT3 and
pT4 adenocarcinomas of no special type. According to our established thresholds, 31 tumors (15%) were classified as low tumor
proportion (TP) (≤ 15% TP), 42 tumors (20%) were classified as high TP (≥ 54% TP), and 133 tumors (65%) were classified as
medium TP. High and low TP were associated with an adverse overall survival in comparison to medium TP (p = 0.001 and p =
0.03). Furthermore, the TP was an independent risk factor of occurrence of distant metastasis next to T status, microsatellite
status, and tumor budding. The 5-year survival rate was 49% in patients with high TP, 48% in patients with low TP, and 68% in
patients with medium TP (p = 0.042, n = 160). Patients with a high TP had less often tumor budding (p = 0.012), lymphovascular
invasion (p = 0.049), and less harvested lymph nodes (p = 0.042) in comparison to low TP tumors. The results provide first
evidence that a high tumor proportion/low stroma proportion is also associated with an adverse prognosis and that this subgroup
might be difficult to identify with other classical histopathologic characteristics that are linked to an adverse prognosis.
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“Over 1.8 million new colorectal cancer cases and 881,000
deaths are estimated to occur in 2018, accounting for about 1
in 10 cancer cases and deaths. Overall, colorectal cancer ranks
third in terms of incidence but second in terms of mortality”
[1]. These estimates illustrate that colorectal cancer is a seri-
ous, worldwide public health problem. Today, tumor-node-
metastasis (TNM) staging of the American Joint Committee
on Cancer (AJCC) is still considered the gold standard for
staging. Irrespective thereof, tumor stroma ratio (TSR) is a
promising new prognostic biomarker in colon cancer, which
could provide additional risk stratification for therapy adap-
tion. In colon cancer, studies were able to show that a high
proportion of intratumoral stromal tissue is associated with a
worse prognosis [2–7]. The prognostic value of the tumor
stroma has also been shown in breast, ovarian, cervical, gas-
tric, and esophageal cancer [8–13]. The complete biological
role of stroma is not fully understood, yet. But it is known that
the stroma has an important role for the supply of the tumor
and the formation of blood vessels and that the stroma can
promote tumorigenesis and metastasis [14–17]. The mesen-
chymal subtype (CMS 4) of the consensus colon cancer sub-
types is associated with a worse prognosis [18]. For colon
cancer, TSR assessment recommendations have been pub-
lished recently [11]. Next to the assessment of stroma propor-
tion by visual estimation, some groups used morphometric
methods for the assessment of the stroma proportion [3, 5,
19, 20]. In rectal cancer, one group investigated the tumor
stroma ratio with computer-aided quantification [21].
The objective of this study was the investigation of the
prognostic significance of stroma/tumor proportion at differ-
ent tumor sites of colon adenocarcinomas (pT3/4) of no spe-
cial type with a simple semiautomatic approach with the open-
source program ImageJ [22].
Materials and methods
Case collective
We retrospectively evaluated 215 patients with colon adeno-
carcinomas of no special type, pT3/4, N± , M0, R0, and at
least 3-month survival after surgery. All patients underwent
surgery at the University Hospital Augsburg between January
2002 and December 2011, and none of the patients had re-
ceived preoperative chemo- or radiotherapy. We excluded 9
patients because of insufficient tumor tissue or insufficient
immunohistochemical staining result (e.g., because of im-
proper fixation) from further analysis. Location: we defined
right-sided tumors from oral to the left colonic flexure
(excluded) and left-sided tumors from the left colonic flexure
(included) to aboral. The evaluation of lymphatic vessel and
venous invasion were performed in each case on all tumor
H&E slides. Follow-up data were provided by the Tumor
Data Management of the University Hospital Augsburg and
complemented with data of the patient files. Tumor budding
was graded according to ITBCC, and in each case, the con-
sensus ratingwas used to define the budding grade, as recently
published [23, 24]. The study protocol was approved by the
Institutional Review Board of University Hospital Augsburg,
Germany.
Assessment of tumor and stroma proportion
In each case, three regions were selected for the assessment of
the tumor proportion (TP)/stroma proportion (SP). These were
(1) FroTP, defined as the region with the deepest infiltration,
measured directly at the invasive front; (2) minimal tumor
proportion (MinTP), defined as the region suspected to have
the highest SP/lowest TP on the slide; and (3) maximum tu-
mor proportion (MaxTP), defined as the region suspected to
have the lowest SP/highest TP. In each case, one representa-
tive H&E section (and a corresponding cytokeratin staining),
which did show the deepest TNM relevant infiltration depth,
was used by Be. Ba. or in difficult cases by cooperation of Be.
Ba. and Be. Ma. for selection of the regions.
The workflow was the following: After an overview of the
H&E slide, we selected the best fitting regions to the above-
mentioned definitions with exclusion of areas containing sig-
nificant amount of blood vessels, necrosis, abscesses, mucin-
ous areas, or large glandular lumen. Glandular tumor lumen
could not be ignored from analysis because of the subsequent
digital workflow (binary coding). Lumen was assigned to tu-
mor proportion. The TP and SP were assessed in a field of
3.58 mm2, but, differing from the recommendations from van
Pelts et al., we used a rectangular selection (side lengths,
2.18 mm and 1.64 mm; field size, 3.58 mm2) instead of a
classical round microscope selection due to usage of a camera
[11]. We selected only regions in which tumor cells were
present at all four borders of the image field. The selection
process of each region was performed using a microscope
(Olympus, BX43F, Tokyo, Japan) with attached camera with
connection to a computer (ProgRes® Speed XTcore5 with
combined software: Capture Pro 2.9.0.1). Digital images were
captured (× 4 objective) of the immunohistochemical stained
slide against a cytokeratin that highlighted the tumor tissue. If
a histochemical stained slide, corresponding to the selected
H&E slide, was already available, we used that one. If not,
we prepared a cytokeratin AE1/AE3 immunostaining accord-
ing to our routine protocol (antibody, cell marque™, mono-
clonal mouse antibody; dilution 1:500; DAB Opti View IHC
Detection Kit; immunostainer, Roche Benchmark Ultra).
Subsequently, the open-source image processing software
ImageJ (Version 1.48 v) was used for TP and SP assessment
[ 2 2 ] . W e u s e d t h e f u n c t i o n p r i n c i p l e t h a t
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immunohistochemically marked brown dark tumor tissue can
be differentiated via binary coding from the surrounding light
stroma tissue (Fig. 1). After binary coding of the taken images
and eliminating the lumen of the tumor cells (run (“make
binary”); run (“fill holes”), Be. Ba. reviewed the result, man-
ually improving the result if necessary (especially, filled up
gaps that were not recognized by the algorithm). After cali-
bration, the images were measured (run (analyze particles)).
To exclude scoring of dust particles, we only scored particles
of at least 0.00023 mm2 in size. We defined tumor proportion
as the following: sum of all tumor areas/3.58 mm2. We defined
stroma proportion as the following: (3.58 mm2- sum of all
tumor areas)/3.58 mm2.
Statistical analysis
All statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS software version 24.0
(SPSS, Chicago, IL, USA)). The database was partitioned into
an exploration and validation set for cutoff determination. The
exploration set (n = 104) included all cases with odd study
numbers of the original set (before exclusion of patients),
and the validation set included all cases with even study num-
bers (n = 102) of the original set. The chi-square test was ap-
plied for comparisons of categorical data. The Mann-Whitney
U test was applied for comparisons between continuous and
ordinal variables between two groups. TheKruskal-Wallis test
was applied for comparisons between continuous and ordinal
variables for more than two groups. Univariate event/survival
analyses were done according to the Kaplan-Meier method
(log-rank test) for assessment of statistical significance. Cox
regression analysis (forward, likelihood ratio) was performed
to investigate the independence of univariate-identified risk
factors. Results were considered statistically significant if
p < 0.05. Continuous variables were demonstrated as mean
± standard deviation (SD), if not otherwise specified.
Results
Patients and scoring results
The mean age of the 206 patients at date of diagnosis was
70.0 ± 11.3 years, the mean follow-up time was 5.3 ±
3.5 years, and 85 (41%) patients died during the follow-up
period. The detailed clinicopathological characteristics are
shown in Table 1.
Themean/median TPwas 36%/36% at FroTP, 32%/31% at
MinTP, and 71%/73% at MaxTP, respectively (Table 2). The
MinTP was assumed to be in the same region as the FroTP in
161 tumors (78%).
Determination of cutoff values
The stroma high group included 76% (FroTP) and 86%
(MinTP) of the cases according to a cutoff at 50%. As the
Fig. 1 a CK-IHC of FroTP of a
tumor with high tumor propor-
tion. b Tumor A before measure-
ment and after manual improve-
ments (see discussion). c Tumor
A after binary coding. d CK-IHC
of FroTP of a tumor with medium
tumor proportion. e Tumor D be-
fore measurement. f MaxTP re-
gion of Tumor D. g CK-IHC of
FroTP of a tumor with low tumor
proportion. h Tumor G before
measurement and after manual
improvements (see discussion). j
Tumor G after binary coding
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tumor proportion in our study, and consequently the corre-
sponding group sizes, differed considerably (if the classical
cutoff was applied) from published literature (discussed later),
we divided our population into an exploration and validation
set for cutoff determination. We used a receiver operating
characteristic (ROC) curve approach to determine the optimal
cutoff point for the prediction of distant metastasis (Fig. 2a,
ROC curve exploration set). As the ROC curve of the explo-
ration set of FroTP has two contrary deviations from the di-
agonal, we determined two cutoff values. We determined the
Table 1 Clinicopathological characteristics
Variable n = 206 High TP (n = 42) Medium TP
(n = 133)
LowTP (n = 31) p value
Mean age (years) 70.0 ± 11.3 73.9 ± 12.2 68.6 ± 11.4 70.8 ± 8.3 0.013
Mean follow-up (years) 5.3 ± 3.5 4.8 ± 3.5 5.7 ± 3.6 4.4 ± 2.7 0.139
Mean lymph node harvest (n) 23 ± 13 19 ± 8 24 ± 14 26 ± 15 0.084
Positive lymph nodes (n) 1.2 ± 2.3 0.9 ± 1.9 1.1 ± 2.3 1.7 ± 2.4 0.485
Sex 0.934
Female 88 43% 17 40% 58 44% 13 42%
Male 118 57% 25 60% 75 56% 18 58%
T status 0.988
pT3 180 87% 37 88% 116 87% 27 87%
pT4 26 13% 5 12% 17 13% 4 13%
Nodal status 0.742
Negative 128 62% 28 67% 82 62% 18 58%
Positive 78 38% 14 33% 51 38% 13 42%
Vascular invasion 0.587
Negative 186 90% 39 93% 118 89% 29 94%
Positive 20 10% 3 7% 15 11% 2 6%
Lymphovascular invasion 0.061
Negative 171 83% 40 95% 106 80% 25 81%
Positive 35 17% 2 5% 27 20% 6 19%
Grading 0.394
Low grade 141 68% 29 69% 94 71% 18 58%
High
grade
65 32% 13 31% 39 29% 13 42%
Tumor budding 0.029
Bd 1 168 82% 38 90% 109 82% 21 68%
Bd 2 25 12% 3 7% 18 14% 4 13%
Bd 3 13 6% 1 2% 6 5% 6 19%
Location 0.999
Right 127 62% 26 62% 82 62% 19 61%
Left 79 38% 16 38% 51 38% 12 39%
Microsatellite status 0.132
MSS 180 87% 38 90% 112 84% 30 97%
MSI 26 13% 4 10% 21 16% 1 3%
Distant metastasis 0.003
No 165 80% 28 67% 116 87% 21 68%
Yes 41 20% 14 33% 17 13% 10 32%
Death 0.003
No 121 59% 16 38% 89 67% 16 52%




Survived 97 61% 18 49% 67 68% 12 48%
Death 63 39% 19 51% 31 32% 13 52%
p values are shown for difference between the low, medium, and high tumor proportion group, classified by cutoffs at FroTP
MSI microsatellite instable, MSS microsatellite stable
Virchows Arch
cutoffs that resulted in the lowest p value in the exploration set
according to the occurrence of distant metastasis by testing
and adjusting. Additionally, we performed subsequently
ROC analyses of MinTP and MaxTP. The analysis of
MaxTP did not reveal a relevant prognostic result (ROC –
curve MaxTP in supplement (S1)), and the analysis of
MinTP was inferior to the analysis of FroTP (ROC – curve
MinTP in supplement (S2)) but showed similar results accord-
ing to the values of the cutoffs at FroTP.
Prognostic analyses
The established cutoff values at FroTP are low TP ≤ 15% TP;
medium TP, 15% < TP < 54%; and high TP ≥ 54% TP.
According to these thresholds, 42 tumors (20%) were classi-
fied as high TP, 31 tumors (15%) were classified as low TP,
and 133 tumors (65%) were classified as medium TP (FroTP).
An overview of the mean tumor proportions in the different
groups is given in Table 2. In the exploration set, a low TP as
well as a high TP was associated with occurrence of distant
metastasis in comparison to medium TP (p = 0.009 and p =
0.015, Fig. 2b). In the validation set, a high TP was also
associatedwith occurrence of distant metastasis in comparison
to medium TP (p = 0.037, Fig. 2c). The association of a low
TP to the occurrence of distant metastasis could not be con-
firmed, although the p value did show a trend towards
significance in comparison to the medium TP group (p =
0.105) (Fig. 2c).
A further Kaplan-Meier analysis in the overall patient pop-
ulation showed a significant adverse overall survival for pa-
tients with a high and low TP in comparison to patients with
mediumTP (p = 0.001 high TP; p = 0.03 low TP, Fig. 3a). The
5-year survival rate was 49% in patients with high TP, 48% in
patients with low TP, and 68% in patients with medium TP
(p = 0.042, n = 160).
We applied the established cutoffs at FroTP region also at
the MinTP region. Thereby, in the overall population (n =
206), 147 patients (71%) were assigned to medium TP group,
25 patients (12%) to the high TP group, and 34 patients (17%)
to the low TP group. A high TP was associated with occur-
rence of distant metastasis and worse overall survival in com-
parison to the medium TP group (p = 0.021 and p = 0.006). A
low TP was associated with occurrence of distant metastasis,
and the p value did show a trend towards significance accord-
ing to an adverse overall survival in comparison to the medi-
um TP group (p = 0.008 and p = 0.094, Fig. 3b).
Multivariate Cox regression
Additionally, we performed a multivariate Cox regression
(forward, likelihood ratio) for the occurrence of distant metas-
tasis including the following risk factors (all variables with a
Table 2 Overview of the tumor
proportion in the different regions Variable All (n = 206) High TP (n = 42) Medium TP (n = 133) Low TP (n = 31) p value
Mean FroTP 36 ± 18 62 ± 7 34 ± 11 11 ± 8 < 0.001
Mean MinTP 32 ± 16 49 ± 17 32 ± 10 11 ± 3 < 0.001
Mean MaxTP 71 ± 13 77 ± 9 70 ± 13 65 ± 15 0.001
p values are shown for difference between the low, medium, and high tumor proportion group, classified by
cutoffs at FroTP
Fig. 2 a ROC curve for the occurrence of distant metastasis in the
exploration set. b Kaplan-Meier curves for the occurrence of distant me-
tastasis in the exploration set (high versus medium tumor proportion p =
0.015; low versus medium tumor proportion p = 0.009). c Kaplan-Meier
curves for the occurrence of distant metastasis in the validation set (high
versus medium tumor proportion p = 0.037; low versus medium tumor
proportion p = 0.105)
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significance level p ≤ 0.1 in univariate analyses): age (≥
70 years versus < 70 years), pT, pN (positive versus negative),
lymphovascular invasion, sidedness, microsatellite status, tu-
mor budding, FroTP (defined as categorical variable), and
MinTP (defined as categorical variable). T status, microsatel-
lite status, tumor budding, as well as FroTP were integrated
into the model as independent risk factors. The hazard ratios
for the low and high TP groups (FroTP) were 2.7 (1.2–6.0,
p = 0.016) and 3.2 (1.6–6.7, p = 0.001) (Table 3).
Furthermore, we performed another multivariate Cox regres-
sion (forward, likelihood ratio) for overall survival including
factors with a significance level p ≤ 0.1 in univariate analyses.
We excluded distant metastasis as risk factor from this analy-
sis, as it indicates tumor progression during follow-up. In this
model, the FroTP, as well as the T status, and the age were
independent risk factors (Table 3).
Characteristics of the different groups
There were significant differences between the three groups
according to the frequency of tumor budding and the age of
the patients (see Table 1). A low TP was associated to tumor
budding (p = 0.012 low TP vs. high TP; p = 0.046 low TP vs.
medium TP) and a higher lymph node harvest (p = 0.042 low
TP vs. high TP; p = 0.480 for low TP vs. medium TP). A high
TP was associated to the absence of tumor budding (p = 0.012
high TP vs. low TP; p = 0.192 high TP vs. medium TP),
lymphovascular invasion (p = 0.049 high TP vs. low TP;
p = 0.018 high TP vs. medium TP), and a lower lymph node
harvest (p = 0.042 high TP vs. low TP; p = 0.057 high TP vs.
medium TP).
Discussion
In this study, we investigated the tumor and stroma proportion
in different regions of 206 pT3 and pT4 adenocarcinomas
(NOS) of the colon in a semiautomatic image analysis ap-
proach. We used the open-source software ImageJ and the
principle that immunohistochemically marked tissue can be
differentiated via binary coding from surrounding light stroma
tissue. We divided our patient population into an exploration
and validation set for cutoff determination. In the validation
set, we could confirm that a high TP/low SP (≥ 54% TP p =
0.037) is associated with occurrence of distant metastasis. In
the overall population, a high TP at FroTP was significantly
associated with a worse overall survival and lower 5-year
survival rate (see Fig. 3 and Table 1). Additionally, a multi-
variate Cox regression did show that a high TP is an indepen-
dent risk factor for occurrence of distant metastasis beside the
T status, microsatellite status, and the tumor budding grade.
The hazard ratio of patients with high TP was 3.2 (1.6–6.7) in
comparison to medium TP (p = 0.001). These findings are
quite surprising, because, so far, only a low TP/high SP has
been linked to a worse prognosis [14]. In this study, a low TP/
high SP (≤ 15%TP) at FroTPwas also associatedwith a worse
Fig. 3 aKaplan-Meier curves for the overall survival based on the overall
patient population and the tumor proportion in the front region (FroTP)
(high versus medium tumor proportion p = 0.001; low versus medium
tumor proportion p = 0.03). b Kaplan-Meier curves for the overall
survival based on the overall patient population and the tumor proportion
in the region with the lowest estimated tumor proportion (MinTP) (high
versus medium tumor proportion p = 0.006; low versus medium tumor
proportion p = 0.094)
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overall survival (p = 0.03 for low TP vs medium TP, Fig. 3),
and the 5-year survival rate was lower than in the medium TP
group (p = 0.042). The results of the prognostic impact of the
MinTP region seem to be similar but all in all a bit inferior
than at FroTP. We could not find a relevant prognostic impact
of the MaxTP region (ROC curve supplement), which empha-
sizes the relevance of the selected region for the assessment.
The different mean TPs in the MinTP (32%), FroTP (36%),
and MaxTP (71%) show the extent of tumor stroma heteroge-
neity. In literature, different tumor regions have been investi-
gated according to their prognostic value. Van Pelt et al. rec-
ommend that the region with the highest stroma proportion on
the slide of the most invasive part should be decisive [11].
Besides that, other groups could show that a high stroma
content of the “whole” tumor, as well as at the luminal surface,
is prognostic [5, 20]. The luminal region has the advantage
that biopsies could be scored, but all in all, the recommenda-
tions of van Pelt et al. seem to be the most promising for a
near-term implementation as an easy diagnostic tool [25].
Interestingly, high TP tumors miss conventional adverse
histological features. These tumors had a low proportion of
tumor budding (p = 0.012 for low TP and p = 0.192 for medi-
umTP) and a low proportion of lymphovascular invasion (p =
0.049 for low TP and p = 0.018 for medium TP). Furthermore,
less lymph nodes have been harvested in these tumors (p =
0.042 for low TP and p = 0.057 for medium TP). Assuming
that the lymph node count is a surrogate indicator of the im-
munological response to the tumor, one might speculate that
Table 3 p values and hazard ratios for univariate and multivariate analyses














P value Overall survival
hazard
ratio, and 95% CI
p
value
Sex 0.18 0.66 0.639
Mean age (years) 0.096 < 0.001 0.002 0.17





> = 23 lymph nodes
< 23 lymph nodes
T status < 0.001 0.018 0.012
T3
T4 4.7 (2.3–9.7) < 0.001 2.2 (1.2–3.9) 0.01
Nodal status (+ vs. -) 0.06 0.25 0.468 0.69
Vascular invasion 0.19 0.49 0.64
Lymphovascular
invasion
0.04 0.39 0.133 0.14
Grading 0.34 0.89 0.697
Tumor budding 0.02 0.34 0.179 1.6 (1.003–2.4) 0.048 0.23
Sidedness 0.047 0.669 0.598 0.071
Microsatellite status 0.03 0.23 0.374
MSS 0.14




High tumor proportion 3.2 (1.6–6.7) 0.001 2.1 (1.3–3.4) 0.004
Medium tumor
proportion
Low tumor proportion 2.7 (1.2–6.0) 0.016 2.0 (1.1–3.7) 0.02
Tumor proportion
(MinTP)
0.009 0.01 0.084 ns ns
Distant metastasis < 0.001 < 0.001
CI confidence interval, MSI microsatellite instable, MSS microsatellite stable, ns not significant
FroTP region at invasion front with deepest infiltration; MinTP region with suspected lowest tumor proportion
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the immunological landscape plays an important role in these
cases [26]. Further studies could clarify this relation more
closely and potentially identify therapeutic opportunities for
this subgroup. Patients with a high TP were significantly older
than the rest of the patients (p = 0.004 for medium TP and p =
0.031 for low TP), but the Cox regression analysis did show
that the adverse prognostic effects are independent of age.
Other significant differences could not be observed (see
Table 1). A morphologic reevaluation of the high TP tumors
revealed no morphologic characteristics.
There are several critical aspects, which have to be taken
into account in interpreting the data of this study. Despite
highly significant results, one has to keep in mind that the data
is from a single center and the design is retrospective with all
the well-known associated drawbacks.
The cutoff determination for TP, for defining this subgroup,
has been determined in an exploration and validation set for the
occurrence of distant metastasis; however, the survival analyses
have been performed in the overall patient population, which
consists of the two sets. The presented approach of TP and SP
assessment based on binary coding with ImageJ has advantages
but also limitations. The presented workflow is not as time and
cost-effective as the conventional assessment on H&E.
However, the necessary input and resources are limited, as the
workflow can be established with basic equipment and only
requires an open-source software. After binary coding, the result
has to be manually reviewed and if necessary reworked. Two
typical causes for rework can be seen in Fig. 1c and j. In Fig. 1j,
the binary coding and the “fill the holes” algorithmmissed to fill
up all holes. Therefore, all lumen had to be stained manually
black (Fig. 1h). Comparing Fig. 1b and c shows that a central
non-tumor part has been falsely stained black. After drawing a
small white connection to the surrounding light stroma area, the
area could be correctly recognized (Fig. 1b). Of course, this kind
of review and reworking process is a source of interobserver
variability, but we consider that of lesser importance because
the anti-cytokeratin staining can be used as model. All in all, it
has been reported that the reproducibility of TSR scoring is good
[11]. Irrespective thereof, we assume that the direct comparabil-
ity of our results to studies in the existing literature is limited. In
comparison to West et al., the median TP was considerably
lower (22/26 percentage points in comparison to FroTP/
MinTP), and after applying the established cutoff at 50% stroma,
a high proportion of patients has been assigned to the high stro-
ma group (76% for FroTP/86% for MinTP) [5]. In most studies,
the high SP group included only 20–30%of all tumors [3, 4, 19].
We assume the main reason for the lower TP and higher SP is
that we have used an anti-cytokeratin stained slide for the selec-
tion of the regions and that we accepted also tumor buds, as part
of the tumor, at the borders of the region (Fig. 1). A further factor
that influenced the TP/SP is that we were not able to ignore
different areas from scoring. Glandular lumen was assessed to
the tumor. Therefore, in this study, the TP corresponds to the
area that is covered and enclosed by tumor. Small areas with
necrotic tissue, smooth muscle tissue, etc., which had to be ac-
cepted in some cases after carefully taking all relevant factors
(tumor tissue at all four part at the edges, overall appearance of
the tumor, etc.) into account, were assigned to stroma propor-
tion. Another reason which might have contributed to the differ-
ence in cutoffs in comparison to the literature is that semiquan-
titative visual estimation appears to underestimate the TSR in
high stroma regions [27]. A limiting factor according to the
evaluation of lymphatic and vascular invasion is that no manda-
tory elastica staining was performed.
Conclusion
This study demonstrates the feasibility of a semiautomatic
image analysis approach for TSR assessment in colon cancer
and in accordancewith literature, and the results confirm that a
high stroma proportion is associated with an adverse progno-
sis. Beyond that, the results provide first evidence that a low
stroma proportion/high tumor proportion might also be an
independent risk factor for the occurrence of distant metastasis
and a worse overall survival. Furthermore, the results indicate
that this subgroup also differs according to the clinicopatho-
logical characteristics from other tumors.
Acknowledgments We would like to thank Louis Bujnoch for language
editing and proofreading.
Authors’ contributions All authors revised the article critically, contrib-
uted with reflective improvements, and approved the final version. Br.
Mä., Be.Ma., and Be. Ba. contributed to the study conception and design.
Ev. Sc., Be. Ba., Ge. Sc., Ma. An., and Be. Ma. contributed to the data
acquisition. Br. Mä., Be. Ma., Be. Ba., and Pa. Ma. contributed to the data
analysis and interpretation.
Funding information Open access funding enabled and organized by
Projekt DEAL. We did not receive an external funding for the study.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethical approval The Institutional Review Board of the Hospital
Augsburg reviewed and approved the study protocol.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate if
changes weremade. The images or other third party material in this article
are included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
Virchows Arch
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A
(2018) Global cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
2. Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS
(2014) The relationship between tumour stroma percentage, the
tumour microenvironment and survival in patients with primary
operable colorectal cancer. Ann Oncol 25:644–651. https://doi.
org/10.1093/annonc/mdt593
3. Mesker WE, Junggeburt JMC, Szuhai K, de Heer P, Morreau H,
Tanke HJ, Tollenaar RA (2007) The carcinoma–stromal ratio of
colon carcinoma is an independent factor for survival compared
to lymph node status and tumor stage. Cell Oncol Off J Int Soc
Cell Oncol 29:387–398. https://doi.org/10.1155/2007/175276
4. Mesker WE, Liefers GJ, Junggeburt JM et al (2009) Presence of a
high amount of stroma and downregulation of SMAD4 predict for
worse survival for stage I&ndash;II colon cancer patients. Cell
Oncol 31:169–178. https://doi.org/10.3233/CLO-2009-0478
5. West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller
W, Treanor D, Quirke P, Grabsch H (2010) The proportion of
tumour cells is an independent predictor for survival in colorectal
cancer patients. Br J Cancer 102:1519–1523. https://doi.org/10.
1038/sj.bjc.6605674
6. Hynes SO, Coleman HG, Kelly PJ, Irwin S, O'Neill RF, Gray RT,
McGready C, Dunne PD, McQuaid S, James JA, Salto-Tellez M,
Loughrey MB (2017) Back to the future: routine morphological
assessment of the tumour microenvironment is prognostic in stage
II/III colon cancer in a large population-based study.
Histopathology 71:12–26. https://doi.org/10.1111/his.13181
7. Eriksen AC, Sørensen FB, Lindebjerg J, Hager H, dePont
Christensen R, Kjær-Frifeldt S, Hansen TF (2018) The prognostic
value of tumour stroma ratio and tumour budding in stage II colon
cancer. A nationwide population-based study. Int J Color Dis 33:
1115–1124. https://doi.org/10.1007/s00384-018-3076-9
8. Kramer CJH, Vangangelt KMH, van Pelt GW, Dekker TJA,
Tollenaar RAEM, Mesker WE (2019) The prognostic value of
tumour–stroma ratio in primary breast cancer with special attention
to triple-negative tumours: a review. Breast Cancer Res Treat 173:
55–64. https://doi.org/10.1007/s10549-018-4987-4
9. Liu J, Liu J, Li J, Chen Y, Guan X,Wu X, Hao C, Sun Y,Wang Y,
Wang X (2014) Tumor-stroma ratio is an independent predictor for
survival in early cervical carcinoma. Gynecol Oncol 132:81–86.
https://doi.org/10.1016/j.ygyno.2013.11.003
10. Courrech Staal EFW, Wouters MWJM, van Sandick JW et al
(2010) The stromal part of adenocarcinomas of the oesophagus:
does it conceal targets for therapy? Eur J Cancer Oxf Engl 1990
46:720–728. https://doi.org/10.1016/j.ejca.2009.12.006
11. van Pelt GW, Kjær-Frifeldt S, van Krieken JHJM, al Dieri R,
Morreau H, Tollenaar RAEM, Sørensen FB, Mesker WE (2018)
Scoring the tumor-stroma ratio in colon cancer: procedure and rec-
ommendations. Virchows Arch Int J Pathol 473:405–412. https://
doi.org/10.1007/s00428-018-2408-z
12. Aurello P, Berardi G, Giulitti D et al (2017) Tumor-stroma ratio is
an independent predictor for overall survival and disease free sur-
vival in gastric cancer patients. Surg J R Coll Surg Edinb Irel 15:
329–335. https://doi.org/10.1016/j.surge.2017.05.007
13. Freeman MR, Li Q, Chung LWK (2013) Can stroma reaction pre-
dict cancer lethality? Clin Cancer Res Off J Am Assoc Cancer Res
19:4905–4907. https://doi.org/10.1158/1078-0432.CCR-13-1694
14. van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van
Krieken J, Tollenaar RAEM, Mesker WE (2018) The tumour-
stroma ratio in colon cancer: the biological role and its prognostic
impact. Histopathology 73:197–206. https://doi.org/10.1111/his.
13489
15. Vermeulen L, De Sousa Melo EF, van der Heijden M et al (2010)
Wnt activity defines colon cancer stem cells and is regulated by the
microenvironment. Nat Cell Biol 12:468–476. https://doi.org/10.
1038/ncb2048
16. Merlos-Suárez A, Barriga FM, Jung P, Iglesias M, Céspedes MV,
Rossell D, Sevillano M, Hernando-Momblona X, da Silva-Diz V,
Muñoz P, Clevers H, Sancho E, Mangues R, Batlle E (2011) The
intestinal stem cell signature identifies colorectal cancer stem cells
and predicts disease relapse. Cell Stem Cell 8:511–524. https://doi.
org/10.1016/j.stem.2011.02.020
17. Dalerba P, Kalisky T, Sahoo D, Rajendran PS, Rothenberg ME,
Leyrat AA, Sim S, Okamoto J, Johnston DM, Qian D, Zabala M,
Bueno J, Neff NF, Wang J, Shelton AA, Visser B, Hisamori S,
Shimono Y, van de Wetering M, Clevers H, Clarke MF, Quake
SR (2011) Single-cell dissection of transcriptional heterogeneity
in human colon tumors. Nat Biotechnol 29:1120–1127. https://
doi.org/10.1038/nbt.2038
18. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A,
Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P,
Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, de Sousa E
Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D,
Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T,
Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend
SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L,
Delorenzi M, Kopetz S, Vermeulen L, Tejpar S (2015) The consen-
sus molecular subtypes of colorectal cancer. Nat Med 21:1350–
1356. https://doi.org/10.1038/nm.3967
19. Huijbers A, RAEM T, van Pelt GW et al (2013) The proportion of
tumor-stroma as a strong prognosticator for stage II and III colon
cancer patients: validation in the VICTOR trial. AnnOncol 24:179–
185. https://doi.org/10.1093/annonc/mds246
20. Hutchins GGA, Treanor D, Wright A, Handley K, Magill L,
Tinkler-Hundal E, Southward K, Seymour M, Kerr D, Gray R,
Quirke P, QUASAR trial collaborators and the UK National
Cancer Research Institute Colorectal Cancer Clinical Studies
Group (2018) Intratumoral stromal morphometry predicts disease
recurrence but not response to 5-fluorouracil-results from the
QUASAR trial of colorectal cancer. Histopathology 72:391–404.
https://doi.org/10.1111/his.13326
21. Geessink OGF, Baidoshvili A, Klaase JM, Ehteshami Bejnordi B,
Litjens GJS, van Pelt G, Mesker WE, Nagtegaal ID, Ciompi F, van
der Laak J (2019) Computer aided quantification of intratumoral
stroma yields an independent prognosticator in rectal cancer. Cell
Oncol Dordr 42:331–341. https://doi.org/10.1007/s13402-019-
00429-z
22. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH image to
ImageJ: 25 years of image analysis. Nat Methods 9:671–675
23. Lugli A, Kirsch R, Ajioka Y et al (2017) Recommendations for
reporting tumor budding in colorectal cancer based on the
International Tumor Budding Consensus Conference (ITBCC)
2016. Mod Pathol Off J U S Can Acad Pathol Inc 30:1299–1311.
https://doi.org/10.1038/modpathol.2017.46
24. Martin B, Schäfer E, Jakubowicz E, Mayr P, Ihringer R, Anthuber
M, Schenkirsch G, Schaller T, Märkl B (2018) Interobserver vari-
ability in the H&E-based assessment of tumor budding in pT3/4
colon cancer: does it affect the prognostic relevance? Virchows
Arch Int J Pathol 473:189–197. https://doi.org/10.1007/s00428-
018-2341-1
Virchows Arch
25. SmitM, van Pelt G, Roodvoets A,Meershoek-Klein Kranenbarg E,
Putter H, Tollenaar R, van Krieken J, Mesker W (2019) Uniform
noting for international application of the tumor-stroma ratio as an
easy diagnostic tool: protocol for a multicenter prospective cohort
study. JMIR Res Protoc 8:e13464. https://doi.org/10.2196/13464
26. Märkl B (2015) Stage migration vs immunology: the lymph node
count story in colon cancer. World J Gastroenterol 21:12218–
12233. https://doi.org/10.3748/wjg.v21.i43.12218
27. Eriksen AC, Andersen JB, Lindebjerg J, dePont Christensen R,
Hansen TF, Kjær-Frifeldt S, Sørensen FB (2018) Does heterogene-
ity matter in the estimation of tumour budding and tumour stroma
ratio in colon cancer? Diagn Pathol 13:20. https://doi.org/10.1186/
s13000-018-0697-9
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Virchows Arch
